280 related articles for article (PubMed ID: 36592175)
1. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
Soorojebally Y; Neuzillet Y; Roumiguié M; Lamy PJ; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Oudard S; Rébillard X; Roy C; Lebret T; Rouprêt M; Audenet F
World J Urol; 2023 Feb; 41(2):345-359. PubMed ID: 36592175
[TBL] [Abstract][Full Text] [Related]
2. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
[TBL] [Abstract][Full Text] [Related]
3. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.
Kim PH; Sukhu R; Cordon BH; Sfakianos JP; Sjoberg DD; Hakimi AA; Dalbagni G; Lin O; Herr HW
BJU Int; 2014 Sep; 114(3):354-9. PubMed ID: 24128299
[TBL] [Abstract][Full Text] [Related]
4. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses.
Soorojebally Y; Neuzillet Y; Lebret T; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Lamy PJ; Oudard S; Rébillard X; Roy C; Roumiguié M; Rouprêt M; Audenet F
Prog Urol; 2023 May; 33(6):307-318. PubMed ID: 37088584
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
Gontero P; Montanari E; Roupret M; Longo F; Stockley J; Kennedy A; Rodriguez O; McCracken SRC; Dudderidge T; Sieverink C; Vanié F; Allasia M; Witjes JA; Sylvester R; Colombel M; Palou J
BJU Int; 2021 Feb; 127(2):198-204. PubMed ID: 32745350
[TBL] [Abstract][Full Text] [Related]
9. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
10. [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
Gonzalo Rodríguez V; Sanz Justo L; de Miguel Santamaría I; Martínez de Iturrate J; Fernández del Busto E
Arch Esp Urol; 2008 Apr; 61(3):377-84. PubMed ID: 18581675
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
[TBL] [Abstract][Full Text] [Related]
13. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
Karaoglu I; van der Heijden AG; Witjes JA
World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
[TBL] [Abstract][Full Text] [Related]
14. Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer.
Feiertag N; Barry E; Abramson M; Park JY; Kovac E; Aboumohamed A; Watts K; Sankin A
Clin Genitourin Cancer; 2023 Apr; 21(2):258-264. PubMed ID: 36621462
[TBL] [Abstract][Full Text] [Related]
15. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
16. Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
Vanneste M; van der Heij B; Christiaansen CE; Berendsen CL; Driessen EJM; Bruins HM
World J Urol; 2023 Aug; 41(8):2173-2178. PubMed ID: 37328699
[TBL] [Abstract][Full Text] [Related]
17. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
18. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.
Mowatt G; Zhu S; Kilonzo M; Boachie C; Fraser C; Griffiths TR; N'Dow J; Nabi G; Cook J; Vale L
Health Technol Assess; 2010 Jan; 14(4):1-331, iii-iv. PubMed ID: 20082749
[TBL] [Abstract][Full Text] [Related]
20. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]